This review highlights the physiological roles of hydrogen sulfide and the development of sulfide-releasing compounds as potential cardioprotective therapeutics.
Answers are grounded in this paper and cite their sources.
Should not yet change cardiovascular practice; leaves open sulfide donor development for targeted trials.
The recognition of hydrogen sulfide (H 2 S) has been evolved from a toxic gas to a physiological mediator, exhibiting properties similar to NO and CO. On the one hand, H 2 S is produced from L‐cysteine by enzymes of cystathionine γ ‐lyase (CSE) and cystathionine β ‐synthase (CBS), 3‐mercaptopyruvate sulfurtransferase (3MST) in combination with aspartate aminotransferase (AAT) (also called as cysteine aminotransferase, CAT); on the other hand, H 2 S is produced from D‐cysteine by enzymes of D‐amino acid oxidase (DAO). Besides sulfide salt, several sulfide‐releasing compounds have been synthesized, including organosulfur compounds, Lawesson’s reagent and analogs, and plant‐derived natural products. Based on garlic extractions, we synthesized S‐propargyl‐L‐cysteine (SPRC) and its analogs to contribute our endeavors on drug development of sulfide‐containing compounds. A multitude of evidences has presented H 2 S is widely involved in the roles of physiological and pathological process, including hypertension, atherosclerosis, angiogenesis, and myocardial infarcts. This review summarizes current sulfide compounds, available H 2 S measurements, and potential molecular mechanisms involved in cardioprotections to help researchers develop further applications and therapeutically drugs.
No takes yet. Share an insight, caveat, or question.
Wen et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: